Europe represents the second-largest market in the Asthma and COPD Drugs Market , valued at USD 10.5 billion in 2024 and holding a 29.70% global share. The region’s growth is driven by a robust healthcare infrastructure, high disease awareness, and supportive regulatory frameworks that encourage innovation and ensure patient access to advanced therapies. Unlike the fragmented payer system in the US, Europe’s centralized regulatory approach through the European Medicines Agency (EMA) provides a cohesive pathway for drug approvals across member states.

The EMA plays a crucial role in facilitating the approval of new respiratory drugs. In Q2 2024, the EMA approved Dupixent for COPD, following its FDA approval, highlighting the region’s alignment with global therapeutic advances. This regulatory environment gives pharmaceutical companies confidence to invest in European markets, knowing that effective treatments can achieve broad access. The EMA’s commitment to expedited reviews for innovative medicines has been instrumental in bringing new biologics and combination therapies to patients faster. Additionally, the European Commission’s focus on strengthening healthcare systems and promoting digital health aligns with the growing adoption of smart inhalers and telemonitoring for respiratory diseases.

Germany is a key contributor, with a 9% share valued at USD 3.18 billion, driven by its strong pharmaceutical sector, high healthcare spending, and a well-established network of respiratory specialists. The country’s focus on precision medicine and digital health integration supports the adoption of advanced inhalation devices and biologic therapies. The United Kingdom follows with an 8% share valued at USD 2.83 billion, supported by the National Health Service’s (NHS) focus on respiratory disease management and digital health integration. The NHS has been proactive in implementing smart inhaler programs and telemonitoring for asthma and COPD patients, often in partnership with industry leaders like AstraZeneca.

Other major European markets, including France, Italy, and Spain, also contribute significantly, with well-established healthcare systems and growing emphasis on preventive care. The competitive landscape in Europe includes global leaders such as Boehringer Ingelheim (Germany) , AstraZeneca (UK) , and GlaxoSmithKline (UK) , alongside specialized biotech firms like Chiesi Farmaceutici, which has a strong focus on inhalation therapies and fixed-dose combinations. Chiesi’s Foster and Trimbow are widely used in Europe for managing chronic asthma and COPD. The company received FDA approval for a new triple therapy inhaler for COPD in Q2 2025, demonstrating its continued innovation.

Public health initiatives aimed at reducing smoking, improving air quality, and promoting early diagnosis further support market growth. The European Centre for Disease Prevention and Control emphasizes strengthening governance and compliance frameworks, which encourages adoption of standardized treatment protocols. As Europe’s population ages and the burden of chronic respiratory diseases remains high, the market is expected to maintain steady expansion, driven by innovation, regulatory support, and a strong commitment to patient care.